

DAFTAR PUSTAKA

- Alsehemi, A.F. *et al.* (2023) 'Assessment of risk factors associated with multidrug-resistant organism infections among patients admitted in a tertiary hospital - a retrospective study', *Saudi Pharm J*, 31(6), pp. 1084–1093.
- Basham, M. A. *et al.* (2020) 'Validity of sequential organ failure assessment and quick sequential organ failure assessment in assessing mortality rate in the intensive care unit with or without sepsis', *Cureus*, 12(10), pp. 1–9.
- Bass, S. N. *et al.* (2015) 'Impact of combination antimicrobial therapy on mortality risk for critically ill Patients with carbapenem-resistant bacteremia', *Antimicrob Agents Chemother*, 59(7), pp. 3748–3753.
- Block, M. dan Blanchard, D. (2023) *Aminoglycoside. StatPearls*. Diakses pada tanggal 23 April 2025. Tersedia dari : <https://www.ncbi.nlm.nih.gov/books/NBK541105/>.
- Burnham, J., Lane, M. dan Kollef, M. (2015) 'Impact of sepsis classification and multidrug-resistance status on outcome among patients treated with appropriate therapy.', *Crit Care Med*, 43, pp. 1580–1586.
- Butler-Laporte, G. *et al.* (2018) 'MRSA colonization status as a predictor of clinical infection: A systematic review and meta-analysis', *J Infect*, 77(6), pp. 489–495.
- Byrne, M. K. *et al.* (2019) 'The drivers of antibiotic use and misuse: the development and investigation of a theory driven community measure', *BMC Public Health*, 19(1425), pp. 1–11.
- Christaki, E. dan Giamarellos-Bourboulis, E. J. (2014) 'The complex pathogenesis of bacteremia: From antimicrobial clearance mechanisms to the genetic background of the host', *Virulence*, 5(1), pp. 57–65.
- Cisneros, J. M. *et al.* (2019) 'Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): An investigator-driven, open-label, randomized, noninferiority controlled trial', *Crit Care*, 23(1), pp. 1–13.
- CLSI (2023). *Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, Edisi 33*. Diakses pada tanggal 5 September 2024. Tersedia dari: www.clsi.org.
- Coburn, B. *et al.* (2012) 'Does this adult patient with suspected bacteremia require blood cultures?', *JAMA*, 308(5), pp. 502–511.
- Cohn, C. M. (2023) 'antimicrobial resistance', *Wolters Kluwer*, pp. 1–9.
- Dettori, S. *et al.* (2023) 'Severe infections caused by difficult-to-treat Gram-negative bacteria', *Curr. Opin. Crit. Care*, 29(5), pp. 438–445.
- Doron, S. dan Davidson, L. E. (2011) 'Antimicrobial stewardship', *Mayo Clinic*

Proc, 86(11), pp. 1113–1123..

EUCAST (2023) *Breakpoint tables for interpretation of MICs and zone diameters*.
Diakses pada tanggal 5 September 2024. Tersedia dari: www.eucast.org

Evans, L. *et al.* (2021) ‘Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021’, *J Intensive Care Med*, 47(11), pp. 1181–1247.

Fernando, S. *et al.* (2018) ‘Prognostic accuracy of the quick sequential organ failure assessment for mortality in patients with suspected infection’, *Ann. Intern. Med.*, 168(4), pp. 266–275.

Gandra, S. *et al.* (2019) ‘The mortality burden of multidrug-resistant pathogens in India: a retrospective, observational study’, *Clin. Infect. Dis.*, 69(4), pp. 563–570. doi: 10.1093/cid/ciy955.

Garcia, E. C. *et al.* (2025) ‘Barriers to health, social and long-term care access among older adults: a systematic review of reviews’. *Int J Equity Health.*, 24(1), pp.72.

Gauba, A. dan Rahman, K. M. (2023) ‘Evaluation of antibiotic resistance mechanisms in gram-negative bacteria’, *Antibiotics*, 12(11), pp.1-30

Gauer, R. *et al.* (2020) ‘Sepsis : diagnosis and management’, *Am. Fam. Physician*, 101(7), pp. 409–418.

Giannella, M. *et al.* (2019) ‘Prognostic utility of the new definition of difficult-to-treat resistance among patients with gram-negative bloodstream infections’, *Open Forum Infect. Dis.*, 6(12), pp. 1–8.

Holmes, A. H. *et al.* (2016) ‘Understanding the mechanisms and drivers of antimicrobial resistance’, *The Lancet*, 387(10014), pp. 176–187.

Huh, K. *et al.* (2020) ‘Impact of difficult-to-treat resistance in gram-negative bacteremia on mortality: retrospective analysis of nationwide surveillance data’, *Clin. Infect. Dis.*, 71(9), pp. E487–E496.

Kadri, S. *et al.* (2017) ‘Difficult-to-treat resistance in gram-negative bacteremia among icu inpatients at 162 u . s . hospitals activity of imipenem-relebactam against gram-negative bacilli from the United States : Smart 2016’, *Clin. Infect. Dis.* 46(1), p. 2017.

Kadri, S. S. *et al.* (2018) ‘Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: Retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents’, *Clin. Infect. Dis.*, 67(12), pp. 1803–1814.

Kalluru, S. *et al.* (2018) ‘Risk factors for infection with multidrug-resistant organisms in haryana, India’, *Am J Infect Control*, 46(3), pp. 341–345.

Kapoor, G., Saigal, S. dan Elongavan, A. (2017) ‘Action and resistance mechanisms of antibiotics : A guide for clinicians basic anatomy of bacterial cell’, *J. Anaesthesiol. Clin. Pharmacol.*, 33(3), pp. 300-305.

- Karlowsky, J. A. *et al.* (2021) 'In vitro activity of imipenem/relebactam and ceftolozane/tazobactam against clinical isolates of Gram-negative bacilli with difficult-to-treat resistance and multidrug-resistant phenotypes-study for monitoring antimicrobial resistance trends, United State', *Clin. Infect. Dis.*, 72(12), pp. 2112–2120.
- Komori, A. *et al.* (2020) 'Characteristics and outcomes of bacteremia among ICU-admitted patients with severe sepsis', *Sci Rep*, 10(1), pp. 1–8.
- Koop, A. (2002) A mathematical model for the efficacy and toxicity of aminoglycoside. Edited by M. S. Thesis. Netherlands: University of Twente.
- Kroneislová, G. *et al.* (2024) 'In vitro activity of antibiotics potentially effective against difficult-to-treat strains of Gram-negative rods: retrospective study', *Sci Rep*, 14(1), pp. 1–8.
- Kumar, N. R. *et al.* (2024) 'Multidrug-resistant sepsis: a critical healthcare challenge', *Antibiotics*, 13(1), pp. 1–38.
- Kyriakidis, I. *et al.* (2021) 'Acinetobacter baumannii antibiotic resistance mechanisms', *Pathogens*, 10(3), pp. 1–31.
- Lambden, S. *et al.* (2019) 'The SOFA score - Development, utility and challenges of accurate assessment in clinical trials', *Crit. Care*, 23(1), pp. 1–9.
- Laupland, K. dan Church, D. (2014) 'Population-based epidemiology and microbiology of community-onset bloodstream infections.', *Clin Microbiol Rev*, 27, pp. 647–664.
- Lin, Z. *et al.* (2022) 'Worse outcomes after readmission to a different hospital after sepsis: a nationwide cohort study', *J Emerg Med*, 63(4), pp. 569–581.
- Longshaw, C. *et al.* (2019) 'In vitro activity of cefiderocol (CFDC), a novel siderophore cephalosporin, against difficult-to-treat-resistant (DTR) Gram-negative bacterial pathogens from the multi-national sentinel surveillance study, SIDERO-WT (2014–2017)', *Open Forum Infect. Dis.*, 6(2), pp. S309–10.
- Lueangarun, S. dan Leelarasamee, A. (2012) 'Impact of inappropriate empiric antimicrobial therapy on mortality of septic patients with bacteremia: A retrospective study', *Interdiscip Perspect Infect Dis.*, 2012(1), pp.1-13
- Lye, D. C. *et al.* (2012) 'The impact of multidrug resistance in healthcare-associated and nosocomial Gram-negative bacteraemia on mortality and length of stay: Cohort study', *Clin. Microbiol. Infect.*, 18(5), pp. 502–508.
- Magiorakos, A. P. *et al.* (2012) 'Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance', *Clin. Microbiol. Infect.*, 18(3), pp. 268–281.
- Mansour, S. R. dan Abdel-Gelil, O. E. (2019) 'Tetracycline and toxicity induced', *GHOA*, 10(4), pp. 177–179.

- Martin, G. S., Mannino, D. M. dan Moss, M. (2006) 'The effect of age on the development and outcome of adult sepsis', *Crit. Care Med.*, 34(1), pp. 15–21.
- Mayr, F., Yende, S. dan Angus, D. (2014) 'Epidemiology of severe sepsis', *Virulence*, 5(1), pp. 4–11.
- Nasution, S.A., *et al.* (eds). (2015) *Buku Panduan Clinical Pathway*. Editor: Sally A Nasution, *et al.* Jakarta: Pusat Penerbitan Ilmu Penyakit Dalam.
- Nejtek, T. *et al.* (2023) 'Bacteremia in patients with sepsis in the icu: does it make a difference?', *Microorganisms*, 11(9), pp.1-30
- Ordooei Javan, A., Shokouhi, S. dan Sahraei, Z. (2015) 'A review on colistin nephrotoxicity', *Eur. J. Clin. Pharmacol.* 71(7), pp. 801–810.
- Palanisamy, N. *et al.* (2023) 'Difficult-to-treat resistant gram-negative blood stream infections – the beginning of a superbug era – a prospective observational study', *Indian J. Med. Microbiol.*, 44, p. 100364.
- Panday, N. *et al.* (2019) 'An overview of positive cultures and clinical outcomes in septic patients', *Crit Care*, 23(1), p. 182.
- Permenkes RI (2021) 'Pedoman Penggunaan Antibiotik', *Permenkes RI*, pp. 1–97.
- Pradipta, I. (2009) *Evaluasi penggunaan antibiotik pada pasien sepsis di bangsal penyakit dalam RSUP Dr. Sardjito, Yogyakarta September-November 2008*. Tesis (S2). Universitas Gadjah Mada, Yogyakarta.
- Pradipta, I. S. *et al.* (2013) 'Antibiotic resistance in sepsis patients: Evaluation and recommendation of antibiotic use', *N. Am. J. Med. Sci.*, 5(6), pp. 344–352.
- Prescott, H. C. *et al.* (2016) 'Late mortality after sepsis: Propensity matched cohort study', *BMJ*, 353, pp. 1–8.
- Purba, A. K. R. *et al.* (2020) 'The burden and costs of sepsis and reimbursement of its treatment in a developing country: An observational study on focal infections in Indonesia', *Int J Infect Dis.*, 96, pp. 211–218.
- Raniputri, K. A. *et al.* (2022) 'Correlation of antibiotic resistance with sepsis incidence, hospital mortality, and time of sepsis onset in community acquired bacterial pneumonia', *J. Respirol. Indones.*, 42(3), pp. 185–191.
- Recioa, R. *et al.* (2020) 'Predictors of mortality in bloodstream infections caused by *Pseudomonas aeruginosa* and impact of antimicrobial resistance and bacterial virulence', *Antimicrob Agents Chemother*, 64(2), pp. 1–13.
- Rudd, K. E. *et al.* (2020) 'Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study', *The Lancet*, 395(10219), pp. 200–211.
- Rus, L. L. *et al.* (2022) 'Microbial resistance to antibiotics and effective antibiotherapy', *Biomedicines*, 10(5), pp. 1-38.
- Saikia, S. dan Chetia, P. (2024) 'Antibiotics: From mechanism of action to resistance and beyond', *Indian J. Microbiol.*, 64(3), pp. 821–845.

- Saputri, L.O., *et al.* (2022) 'Program pengendalian resistensi antibiotik di tengah pandemik covid-19 bagi tenaga kesehatan di Indonesia', *Jurnal Abdi Insani*, 9(4), pp. 1780–1788.
- Sari, S. K., Dahesihdewi, A. dan Sianipar, O. (2023) 'Blood culture positivity rate: antibiographical therapy impact before sample collection in sepsis patients', *IJCPML*, 29(3), pp. 250–255.
- Shields, R. K. *et al.* (2016) 'Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant enterobacteriaceae infections', *Clin. Infect. Dis.*, 63(12), pp. 1615–1618.
- Shorr, A. F. *et al.* (2011) 'Inappropriate antibiotic therapy in Gram-negative sepsis increases hospital length of stay', *Crit. Care Med.*, 39(1), pp. 46–51.
- Singer, M. *et al.* (2016) 'The third international consensus definitions for sepsis and septic shock (Sepsis-3)', *JAMA*, 315(8), pp. 801–810.
- Soleha, T. (2019) 'Uji kepekaan terhadap antibiotik', *Juke Unila*, 5(9), pp. 119–123.
- Strich, J. R., Heil, E. L. dan Masur, H. (2021) 'Considerations for empiric antimicrobial therapy in sepsis and septic shock in an era of antimicrobial resistance', *J Infect Dis*, 222(2), pp. S119–S131.
- Sulis, G. *et al.* (2022) 'Exposure to World Health Organization's AWaRe antibiotics and isolation of multidrug resistant bacteria: a systematic review and meta-analysis', *Clin. Microbiol. Infect.*, 28(9), pp. 1193–1202.
- Sumantri, S. (2012) *Tinjauan Immunopatogenesis dan Tatalaksana Sepsis*. Referat, Departemen Ilmu Penyakit Dalam, Fakultas Kedokteran Universitas Indonesia, Jakarta.
- Sweeney, T. E., Liesenfeld, O. dan May, L. (2019) 'Diagnosis of bacterial sepsis: why are tests for bacteremia not sufficient?', *Expert Rev. Mol. Diagn.*, 19(11), pp. 959–962.
- Tabah, A. *et al.* (2023) 'EUROBACT-2 Study Group, ESICM, ESCMID ESGCIP and the OUTCOMEREA Network. Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study', *Intensive Care Med*, 49, pp. 178–190.
- Tameru, R. P., Suprptomo, R. dan Setijanto, E. (2022) 'Comparison between SIRS and qSOFA score for predicting mortality and length of stay sepsis patients in ICU of Dr Moewardi Hospital Surakarta', *Smart Med J*, 5(1), p. 22.
- Tang, K. W. K., Millar, B. C. dan Moore, J. E. (2023) 'Antimicrobial resistance (AMR)', *Br. J. Biomed. Sci.*, 80(6), pp. 1–11.
- Tankeshwar, A. (2025) *Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC)*, *Bacteriology*. Diakses pada tanggal 24

April 2025. Tersedia dari: https://microbeonline.com/minimum-inhibitory-concentration-and-minimum-bactericidal-concentration-mbc/#Agar_dilution_method

- Uddin, T. M. *et al.* (2021) 'Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects', *J. Infect. Public Heal.*, 14(12), pp. 1750–1766.
- Vera, S. *et al.* (2015) 'Novel relationships between oxidative stress and angiogenesis-related factors in sepsis: New biomarkers and therapies', *Annal. Med.*, 47(4), pp. 289–300.
- Vincent, J.-L. *et al.* (2020) 'EPIC III Investigators. Prevalence and outcomes of infection among patients in intensive care units in 2017', *JAMA*, 323, pp. 1478–1487.
- Virgonita, S dan Zulkarnain, A.K. (2012) 'Pola penggunaan obat pada pasien sirosis hati di instalasi rawat inap bangsal penyakit dalam rumah sakit DR. Sardjito Yogyakarta', *Maj. Farmaseutik*, 8(3), p. 218.
- Wang, H. E. *et al.* (2012) 'Chronic medical conditions and risk of sepsis', *PLoS ONE*, 7(10), pp. 6–13.
- Yaghoubi, S. *et al.* (2022) 'Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review', *EJCMID*, 41(7), pp. 1003–1022.
- Yiang, G. *et al.* (2021) 'Early screening of risk for multidrug-resistant organisms in the emergency department in patients with pneumonia and early septic shock: single-center, retrospective cohort study', *Shock*, 55(2), pp. 198–209.
- Zanichelli, V. *et al.* (2023) 'The WHO AWaRe (Access, Watch, Reserve) antibiotic book and prevention of antimicrobial resistance', *Bull. World Health Organ.*, 101(4), pp. 290–296.